# A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06623136/  
OnCo record `nct06623136` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by Elpiscience (Suzhou) Biopharma, Ltd., now recruiting.

## Summary

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06623136 by Elpiscience (Suzhou) Biopharma, Ltd., with 40 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: ES102, Toripalimab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06623136
- Phase: 2
- Setting: An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- Sponsor: Elpiscience (Suzhou) Biopharma, Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06623136: https://clinicaltrials.gov/study/NCT06623136

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Elpiscience (Suzhou) Biopharma](https://onco.cc/companies/elpiscience-suzhou-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06623136.json